GlassScriptPhysician profile
Matthew Alan Rand
NPI 1427670520
$3,072.99
in general payments reported to CMS, 2019-2025
14 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.67 · 2023: $481 · 2024: $1,402 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513 · Education: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.91 |
| Education | $497.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,048.78 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $380.03 | 2023-2025 | Sotyktu |
| Abbvie INC. | $355.39 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $245.98 | 2024-2025 | |
| Lilly USA, LLC | $211.10 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $204.10 | 2022-2024 | Ilumya |
| Ucb, INC. | $166.09 | 2024-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Amgen INC. | $91.04 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $88.95 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $67.87 | 2024-2025 | |
| Organon LLC | $48.90 | 2025 | |
| Dermavant Sciences, INC. | $45.64 | 2024 | Vtama |
| Biofrontera INC. | $20.12 | 2024 | Ameluz, Rhodoled Xl, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.